AEQUITAS NEO EXCHANGE · HELP
+11.47% · +$1.23 · Vol 1.7M
Market closed · last close 4:00 PM ET · price as of 19:59:03 ET
Cybin Inc

Cybin Inc

Pharmaceuticals
$11.95
Card
Relationship Map

Follow $HELP

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $HELP by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
HELP
Cybin Inc
Sat Oct 10 · completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

64/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Sat Oct 10 · completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is HELP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading HELP catalysts
About Cybin Inc
Pharmaceuticals
Listed since
2020
Employees
50
Country
CA

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.75
Day high
$12.09
Day low
$10.45
Previous close
$10.72
52W high
$14.02
-14.76% from high
52W low
$3.87
80% of range
Market cap
$1.9M
EPS
$-4.2503
Beta
1.32
Shares out
73.1M
Volume
1.7M
1.03× rel vol
Avg volume
1.6M
VWAP
$11.49
Price history computed in-house
1W
+2.14%
1M
-7.86%
3M
+78.36%
SMA 50 $11.99 · below
SMA 200 Not reported · Not reported
52W position 80%

HELP overview

Veridion Score
64
Registered · 2026-10-09
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around HELP.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading HELP Form 4 filings
Public disclosures

Congress activity in HELP

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

HELP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HELP in this window.
Lobbying spend

HELP lobbying filings, year to date.

Registered lobbying filings matched to Cybin Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for HELP in this window.
Loading news for HELP
Analyst ratings
Sovereign unlock shows live analyst consensus for HELP.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.